Substituted pyrazoles as sting modulators
Disclosed herein are heterocyclic compounds that may be used as STING modulators, process for synthesis and uses of such compounds in treatment of various diseases including cancers. In an aspect, the compounds are of Formula (I).
1 . A compound of formula (II):
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof,
wherein:
Q 1 is H, halogen, or OH;
R 3 is H, halogen, or —C 1-8 alkyl;
R 4 is O—C 1-6 alkyl; and
L 1 is —CH 2 —;
L 2 is —CH═CH— or —C(CH 3 )═C(CH 3 )—;
L 3 is —CH 2 —;
Q 2 is H, halogen, or OH;
R 8 is H, halogen, or —C 1-8 alkyl; and
R 9 is —O—C 1-6 alkyl-(saturated 4- to 7-membered heterocyclyl), wherein the 4- to 7-membered heterocyclyl comprises one, two, or three heteroatoms independently selected from the group consisting of N, O, and S.
2 . The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
Q 1 is H; and
Q 2 is H.
3 . The compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof, wherein:
R 3 is H or halogen; and
R 8 is H or halogen.
4 . The compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
R 4 is —OCH 3 ; and
R 9 is —OCH(morpholin-4-yl)CH 2 CH 3 , —OCH 2 CH(morpholin-4-yl)CH 3 , or —OCH 2 CH 2 CH 2 (morpholin-4-yl).
5 . The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt or tautomer thereof.
6 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient together with a compound of claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.